1180 related articles for article (PubMed ID: 26149830)
21. CDK4-6 inhibitors in breast cancer: current status and future development.
Choo JR; Lee SC
Expert Opin Drug Metab Toxicol; 2018 Nov; 14(11):1123-1138. PubMed ID: 30360668
[TBL] [Abstract][Full Text] [Related]
22. Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences.
Braal CL; Jongbloed EM; Wilting SM; Mathijssen RHJ; Koolen SLW; Jager A
Drugs; 2021 Feb; 81(3):317-331. PubMed ID: 33369721
[TBL] [Abstract][Full Text] [Related]
23. [Pharmacological Effects of CDK4 & 6 Selective Inhibitor Abemaciclib in Hormone Receptor-Positive Breast Cancer].
Tamaki C; Hayashi S; Sato A; Maeda K; Sakaguchi S; Buchanan S; Enatsu S
Gan To Kagaku Ryoho; 2019 Sep; 46(9):1405-1411. PubMed ID: 31530780
[TBL] [Abstract][Full Text] [Related]
24. CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib.
Laderian B; Fojo T
Semin Oncol; 2017 Dec; 44(6):395-403. PubMed ID: 29935901
[TBL] [Abstract][Full Text] [Related]
25. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine.
Gelbert LM; Cai S; Lin X; Sanchez-Martinez C; Del Prado M; Lallena MJ; Torres R; Ajamie RT; Wishart GN; Flack RS; Neubauer BL; Young J; Chan EM; Iversen P; Cronier D; Kreklau E; de Dios A
Invest New Drugs; 2014 Oct; 32(5):825-37. PubMed ID: 24919854
[TBL] [Abstract][Full Text] [Related]
26. Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancer.
Tamura K
Jpn J Clin Oncol; 2019 Dec; 49(11):993-998. PubMed ID: 31665472
[TBL] [Abstract][Full Text] [Related]
27. A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
Bilgin B; Sendur MAN; Şener Dede D; Akıncı MB; Yalçın B
Curr Med Res Opin; 2017 Sep; 33(9):1559-1569. PubMed ID: 28657360
[TBL] [Abstract][Full Text] [Related]
28. CDK4/6 inhibition suppresses tumour growth and enhances the effect of temozolomide in glioma cells.
Cao Y; Li X; Kong S; Shang S; Qi Y
J Cell Mol Med; 2020 May; 24(9):5135-5145. PubMed ID: 32277580
[TBL] [Abstract][Full Text] [Related]
29. Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance.
Martin CA; Cullinane C; Kirby L; Abuhammad S; Lelliott EJ; Waldeck K; Young RJ; Brajanovski N; Cameron DP; Walker R; Sanij E; Poortinga G; Hannan RD; Pearson RB; Hicks RJ; McArthur GA; Sheppard KE
Int J Cancer; 2018 May; 142(10):2139-2152. PubMed ID: 29243224
[TBL] [Abstract][Full Text] [Related]
30. Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer.
Martin M; Garcia-Saenz JA; Manso L; Llombart A; Cassinello A; Atienza M; Ringeisen F; Ciruelos E
Future Oncol; 2020 Nov; 16(33):2763-2778. PubMed ID: 32781837
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma.
Aliagas E; Alay A; Martínez-Iniesta M; Hernández-Madrigal M; Cordero D; Gausachs M; Pros E; Saigí M; Busacca S; Sharkley AJ; Dawson A; Palmero R; Ruffinelli JC; Padrones S; Aso S; Escobar I; Ramos R; Llatjós R; Vidal A; Dorca E; Varela M; Sánchez-Céspedes M; Fennell D; Muñoz-Pinedo C; Villanueva A; Solé X; Nadal E
Br J Cancer; 2021 Nov; 125(10):1365-1376. PubMed ID: 34588615
[TBL] [Abstract][Full Text] [Related]
32. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
[TBL] [Abstract][Full Text] [Related]
33. Abemaciclib sensitizes HPV-negative cervical cancer to chemotherapy via specifically suppressing CDK4/6-Rb-E2F and mTOR pathways.
Liu Y; Zhao R; Fang S; Li Q; Jin Y; Liu B
Fundam Clin Pharmacol; 2021 Feb; 35(1):156-164. PubMed ID: 32446293
[TBL] [Abstract][Full Text] [Related]
34. SPH3643: A novel cyclin-dependent kinase 4/6 inhibitor with good anticancer efficacy and strong blood-brain barrier permeability.
Liao X; Hong Y; Mao Y; Chen N; Wang Q; Wang Z; Zhang L; Wang L; Shi C; Shi W; Ge H; Li A; Li X; Xia G; Liu Y
Cancer Sci; 2020 May; 111(5):1761-1773. PubMed ID: 32103527
[TBL] [Abstract][Full Text] [Related]
35. Targeting breast cancer with CDK inhibitors.
Mayer EL
Curr Oncol Rep; 2015; 17(5):443. PubMed ID: 25716100
[TBL] [Abstract][Full Text] [Related]
36. CDK 4/6 inhibitors and stereotactic radiation in the management of hormone receptor positive breast cancer brain metastases.
Figura NB; Potluri TK; Mohammadi H; Oliver DE; Arrington JA; Robinson TJ; Etame AB; Tran ND; Liu JK; Soliman H; Forsyth PA; Sahebjam S; Yu HM; Han HS; Ahmed KA
J Neurooncol; 2019 Sep; 144(3):583-589. PubMed ID: 31399935
[TBL] [Abstract][Full Text] [Related]
37. An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer.
Robert M; Frenel JS; Bourbouloux E; Rigaud DB; Patsouris A; Augereau P; Gourmelon C; Campone M
Drugs; 2018 Sep; 78(13):1353-1362. PubMed ID: 30143968
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth.
Hashizume R; Zhang A; Mueller S; Prados MD; Lulla RR; Goldman S; Saratsis AM; Mazar AP; Stegh AH; Cheng SY; Horbinski C; Haas-Kogan DA; Sarkaria JN; Waldman T; James CD
Neuro Oncol; 2016 Nov; 18(11):1519-1528. PubMed ID: 27370397
[TBL] [Abstract][Full Text] [Related]
39. CDK4/6 inhibitors in breast cancer therapy: Current practice and future opportunities.
Lynce F; Shajahan-Haq AN; Swain SM
Pharmacol Ther; 2018 Nov; 191():65-73. PubMed ID: 29933034
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic drug evaluation of abemaciclib for advanced breast cancer.
Robert M; Frenel JS; Bourbouloux E; Berton Rigaud D; Patsouris A; Augereau P; Gourmelon C; Campone M
Expert Opin Drug Metab Toxicol; 2019 Feb; 15(2):85-91. PubMed ID: 30577708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
